Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Viruses 2012, 4(2), 280-308; doi:10.3390/v4020280
Review

Henipavirus Mediated Membrane Fusion, Virus Entry and Targeted Therapeutics

1
, 2
, 2
 and 1,*
Received: 30 December 2011; in revised form: 30 January 2012 / Accepted: 30 January 2012 / Published: 13 February 2012
(This article belongs to the Special Issue Virus-Induced Membrane Fusion)
View Full-Text   |   Download PDF [2277 KB, uploaded 13 February 2012]   |   Browse Figures
Abstract: The Paramyxoviridae genus Henipavirus is presently represented by the type species Hendra and Nipah viruses which are both recently emerged zoonotic viral pathogens responsible for repeated outbreaks associated with high morbidity and mortality in Australia, Southeast Asia, India and Bangladesh. These enveloped viruses bind and enter host target cells through the coordinated activities of their attachment (G) and class I fusion (F) envelope glycoproteins. The henipavirus G glycoprotein interacts with host cellular B class ephrins, triggering conformational alterations in G that lead to the activation of the F glycoprotein, which facilitates the membrane fusion process. Using the recently published structures of HeV-G and NiV-G and other paramyxovirus glycoproteins, we review the features of the henipavirus envelope glycoproteins that appear essential for mediating the viral fusion process, including receptor binding, G-F interaction, F activation, with an emphasis on G and the mutations that disrupt viral infectivity. Finally, recent candidate therapeutics for henipavirus-mediated disease are summarized in light of their ability to inhibit HeV and NiV entry by targeting their G and F glycoproteins.
Keywords: paramyxovirus; entry; attachment glycoprotein; fusion glycoprotein; membrane fusion; receptor; ephrin-B2; ephrin-B3; inhibitor; antibody; immunotherapy paramyxovirus; entry; attachment glycoprotein; fusion glycoprotein; membrane fusion; receptor; ephrin-B2; ephrin-B3; inhibitor; antibody; immunotherapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Steffen, D.L.; Xu, K.; Nikolov, D.B.; Broder, C.C. Henipavirus Mediated Membrane Fusion, Virus Entry and Targeted Therapeutics. Viruses 2012, 4, 280-308.

AMA Style

Steffen DL, Xu K, Nikolov DB, Broder CC. Henipavirus Mediated Membrane Fusion, Virus Entry and Targeted Therapeutics. Viruses. 2012; 4(2):280-308.

Chicago/Turabian Style

Steffen, Deborah L.; Xu, Kai; Nikolov, Dimitar B.; Broder, Christopher C. 2012. "Henipavirus Mediated Membrane Fusion, Virus Entry and Targeted Therapeutics." Viruses 4, no. 2: 280-308.



Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert